Amgen Inc (AMGN)

AMGN (NASDAQ:Drugs)
$137.63
neg -1.75
-1.26%
Today's Range: 137.52 - 139.93 | AMGN Avg Daily Volume: 2,900,100
Last Update: 09/02/14 - 12:31 PM EDT
Volume: 1,452,970
YTD Performance: 22.18%
Open: $139.62
Previous Close: $139.38
52 Week Range: $105.76 - $139.73
Oustanding Shares: 759,607,230
Market Cap: 105,874,055,717
6-Month Chart
TheStreet Ratings Grade for AMGN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 5 6 8 8
Moderate Buy 2 2 1 1
Hold 8 9 10 10
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.17 2.15 2.08 2.08
Latest Dividend: 0.61
Latest Dividend Yield: 1.75%
Dividend Ex-Date: 08/12/14
Price Earnings Ratio: 21.34
Price Earnings Comparisons:
AMGN Sector Avg. S&P 500
21.34 21.40 29.06
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
20.16% 28.04% 154.39%
GROWTH 12 Mo 3 Yr CAGR
Revenue 8.20 0.24 0.07
Net Income 16.90 0.10 0.03
EPS 20.30 0.40 0.12
Earnings for AMGN:
EBITDA 7.35B
Revenue 18.68B
Average Earnings Estimates
Qtr (09/14) Qtr (12/14) FY (12/14) FY (12/15)
Average Estimate $2.06 $2.17 $8.24 $8.93
Number of Analysts 2 2 2 2
High Estimate $2.10 $2.24 $8.37 $9.30
Low Estimate $2.01 $2.11 $8.12 $8.56
Prior Year $1.93 $1.81 $7.57 $8.24
Growth Rate (Year over Year) 6.48% 20.17% 8.92% 8.31%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

Timothy Collins

 | Aug 26, 2014 | 11:54 AM EDT
Checking two biotech charts.
By

Jim Cramer

 | Aug 14, 2014 | 12:18 PM EDT

Amgen's gain is pure insanity from a stock picker's point of view.

By

Jim Cramer

 | Aug 4, 2014 | 11:45 AM EDT

These quality names look appealing on the basis of 30-week moving average.

bullishAmgen estimates, target raised at Credit Suisse

Jul 30, 2014 | 7:13 AM EDT

Shares of AMGN now seen reaching $135, according to Credit Suisse. Estimates also increased, given the company's new guidance. Neutral rating. 

By

Carolyn Boroden

 | Jun 27, 2014 | 9:00 AM EDT

On a daily time frame, as long as it holds a key support level, it's a possible buy.

By

David Katz

 | Jun 20, 2014 | 11:00 AM EDT

Hologic, Symantec and TE Connectivity could all benefit from the current M&A binge.

By

Dan Fitzpatrick

 | Jun 11, 2014 | 11:30 AM EDT

For now, just let the market do the heavy lifting for you.

By

Ed Ponsi

 | May 28, 2014 | 10:30 AM EDT

After a decline, the sector has built a base, and these names are breaking out.

By

David Katz

 | May 16, 2014 | 12:00 PM EDT

Spice up your portfolio with some takeover bait.

By

David Katz

 | May 6, 2014 | 2:30 PM EDT

Its pipeline appears strong enough to overcome patent-expiration issues.

Before you get sucked into the hype surrounding the long lines at $DNKN's Santa Monica sto...
Shares of Altria appear to have reached a turning point. The stock had a very impres...
Market continue to be mixed at mid-day as S&P 500 has moved under the 2,000 level once...
China cracks down on "core participants" in pyramid schemes. No names mentioned. Shanghai ...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.